Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile

Author(s): D. Kouvelas, A. Goulas, G. Papazisis, C. Sardeli and C. Pourzitaki

Volume 15, Issue 30, 2009

Page: [3464 - 3475] Pages: 12

DOI: 10.2174/138161209789206971

Price: $65

Abstract

PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.

Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy